Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study.

Takeya Kitta,Amanda Darekar,Bimal Malhotra,Mohamed H Shahin,Philip Jones, Monica Lindsay,Sharon Mallen,Alejandra Nieto,Tim J Crook

Journal of pediatric urology（2023）

引用 1|浏览8

暂无评分

摘要

Fesoterodine has a favorable benefit-risk profile in 6‒<18-year-old patients with NDO and may represent an additional option for pediatric NDO treatment.

查看译文

关键词

Anticholinergic,Antimuscarinics,Clinical study,Neurogenic detrusor overactivity,Pediatrics,Therapeutics

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要